Type Fab fragment ATC code V03AB37 (WHO) | Trade names Praxbind CAS Number 1362509-93-0 | |
 | ||
How to pronounce idarucizumab praxbind memorizing pharmacology extended explanation
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody designed for the reversal of anticoagulant effects of dabigatran.
This drug was developed by Boehringer Ingelheim Pharmaceuticals. A large study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation by dabigatran within minutes. It was FDA approved in October 2015. In the United States the wholesale cost is $3500 US.
References
Idarucizumab Wikipedia(Text) CC BY-SA